Institutional Cluster

CRVS

Corvus Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed1mo ago
Institutional cluster: 15 buyers, 3 sellers (bullish)
Actionable Insight ▲ Bullish

The cluster is broad and conviction-driven, with both passive and active managers adding. The $250K insider buy adds corroboration. However, the 45-day 13F lag means positions may have been partially unwound. Monitor for a catalyst (e.g., pipeline update) that could explain the shared thesis, and watch for follow-on insider buying or further 13F accumulation in Q3.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d
CRVS ▼ -14.11% at T+20d
LONG call ✗ call lost -14.11% · α vs SPY -13.58% · entry $14.46 → $12.42
Next anchor: T+60d in 6w
Latest observation: T+26 -18.34% FF3 residual α
Entry anchored
Aug 21, 2026
via day open
T+1d
-2.56%
call -2.56% · α -2.26%
$14.09
settled 6w ago
T+5d
-2.07%
call -2.07% · α -2.55%
$14.16
settled 5w ago
T+20d
-14.11%
call -14.11% · α -13.58%
$12.42
settled 11d ago
T+60d
—
call — · α —
—
in 6w

Executive Summary

A strong institutional cluster formed in CRVS during 2026-Q2, with 15 buyers accumulating $24.8M in holdings (net +$14.6M) against only 3 sellers trimming $17.1M. The buying was dominated by mega-passive firms (BofA, Wells Fargo, UBS) and active asset managers (Susquehanna, Citigroup) doubling or adding positions, while the selling was concentrated in a single large trim by Morgan Stanley (-$16.5M). The cluster is reinforced by a 13F × Form 4 confluence score of 65/100 ('conviction'), with one insider making a $250K open-market purchase, suggesting shared conviction around a catalyst.

Key Financial Metrics

Direction
accumulating
Buy Value
$24.8M
Sell Value
$17.1M
Net Flow
-$2.5M

Institutional Positions

Net institutional flow: -$2.5M

▲ Buyers (15)

InstitutionActionChangePosition ValueValue Δ
BofADOUBLED+219.7%$11.3M$7.9M
Susquehanna International GroupDOUBLED+393.4%$2.8M$2.3M
CitigroupDOUBLED+676.8%$1.7M$1.5M
UBSADD+37%$5.9M$1.7M

▼ Sellers (3)

InstitutionActionChangePrev ValueValue Δ
Morgan StanleyTRIM-46.2%$36.6M-$16.5M
Td Asset ManagementTRIM-33.2%$1.8M-$576.3K

Key Facts

  • 15 institutional buyers vs 3 sellers in 2026-Q2
  • Aggregate buyer holdings: $24.8M (net change +$14.6M)
  • BofA doubled its position (+219.7%) to $11.3M, the largest buyer
  • Susquehanna (+393.4%) and Citigroup (+676.8%) also doubled positions
  • Morgan Stanley trimmed 46.2% of its stake, selling $16.5M
  • 13F × Form 4 confluence score 65/100 — one insider bought $250K open-market
  • 93% of analysts rate the stock Buy or Strong Buy

Financial Impact

15 institutions accumulated $24.8M in CRVS during Q2, with net buying of $14.6M, while 3 sellers reduced holdings by $17.1M (net cluster -$2.5M)

institutional ownershipfloat concentration

Risk Factors

  • 13F data is 45+ days stale; cluster may have already been unwound
  • Morgan Stanley's large trim (-$16.5M) offsets much of the buying
  • Historical reports on CRVS have a 20% win rate at T+20, suggesting poor timing on prior calls
  • Score calibration shows score-6 filings have only ~50% observed probability of up-move at T+20 in this segment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-CRVS-2026-Q2
9 reports for CRVS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CRVS — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
Institutional Cluster
BULLISH ★ 6/10
$14.46 $12.42▼ −14.11%▼ −13.58%—
Jul 22, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$13.68 $14.33▲ +4.75%▲ +1.44%—
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$11.60 $16.20▲ +39.66%▲ +37.76%—
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$13.66 $11.93▼ −12.63%▼ −11.77%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$15.55 $11.12▼ −28.49%▼ −28.51%—
Apr 24, 2026
23w ago
DEFA14A
NEUTRAL ★ 4/10
$15.92 $12.83▼ −19.41%▼ −24.37%—
Apr 21, 2026
23w ago
Press Release
NEUTRAL ★ 4/10
$17.14 $12.21▼ −28.76%▼ −33.68%—
Mar 12, 2026
29w ago
Press Release
BULLISH ★ 8/10
$15.32 $15.17▼ −0.98%▼ −4.57%—
Mar 5, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$15.80 $14.71▼ −6.87%▼ −4.82%—
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 21, 2026